Form 4: Bioventus Director Michelle McMurry-Heath Boosts Stake with RSU Vesting and New Equity Grant

Bioventus Inc. Director Michelle McMurry-Heath reported the acquisition of 26,493 Class A Common Stock shares through RSU vesting and received a new grant of 32,282 Restricted Stock Units.

Summary

• Michelle McMurry-Heath, a Director at Bioventus Inc. (BVS), reported transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs).
• On June 2, 2025, 26,493 Restricted Stock Units (RSUs) vested, resulting in the acquisition of 26,493 shares of Class A Common Stock at a price of $0 per share.
• Following this transaction, Ms. McMurry-Heath directly beneficially owns 74,698 shares of Class A Common Stock.
• Additionally, on June 3, 2025, Ms. McMurry-Heath was granted 32,282 new Restricted Stock Units at a price of $0.
• These newly granted RSUs are contingent rights to receive one share of Class A Common Stock each and will vest on the earlier of the day immediately preceding the Issuer's first Annual Meeting of Stockholders following the grant date or the first anniversary of the grant date, subject to continued service on the Board.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The director increased their direct ownership through RSU vesting and received a new equity grant, indicating continued alignment and commitment to the company. There were no sales reported.

Positives

• Director Michelle McMurry-Heath increased her direct beneficial ownership of Class A Common Stock by 26,493 shares through the vesting of previously granted Restricted Stock Units, indicating continued alignment with shareholder interests.
• The grant of an additional 32,282 Restricted Stock Units to a director suggests ongoing commitment and incentivization of key leadership.

Future Outlook

The newly granted 32,282 Restricted Stock Units are scheduled to vest on the earlier of the day immediately preceding the Issuer's first Annual Meeting of Stockholders following the grant date or the first anniversary of the grant date, contingent on the director's continued service.

Industry Context

This filing reflects standard equity compensation practices for directors in publicly traded companies, aiming to align management and director interests with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a common practice across various industries, including the healthcare and medical device sectors where Bioventus operates.
• The vesting schedule tied to continued service and annual meetings is typical for such equity grants, aligning with corporate governance best practices for director incentivization.

Corporate Governance

Related Party Transactions

• The acquisition of Class A Common Stock through RSU vesting and the grant of new Restricted Stock Units to a director constitute related party transactions as they involve compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The increase in director ownership through RSU vesting and the new RSU grant can be viewed positively as it aligns the director's financial interests with those of the shareholders, potentially signaling confidence in the company's future.

Next Steps

• The 32,282 Restricted Stock Units granted on June 3, 2025, are expected to vest on the earlier of the day immediately preceding the Issuer's first Annual Meeting of Stockholders following the grant date or the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

Bioventus Inc., BVS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Acquisition, Director Compensation, Equity Grant, Michelle McMurry-Heath